ClinicalTrials.gg
Active, not recruitingNCT06731621PAT-DAUpdated Oct 26, 2026

Psilocybin for Treatment-Resistant Depression in Autism

A Phase 1 interventional study of Psilocybin in Treatment Resistant Depression and Autism Spectrum Disorder, sponsored by Centre for Addiction and Mental Health. Active, not recruiting at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Centre for Addiction and Mental Health · Phase 1, Interventional, and Treatment

How we know

Updated Oct 26, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant — 9 open to participants now, 14 under way, 2 of them phase 3. Psilocybin · Depressive Disorder, Treatment-Resistant.

Enrollment
20th of 25
18 · median 30
Started
2024
with 5 others
Phase 1
2 of 25
none open now
Primary completion
2027-01
later than 6 of 13 live
Registered
20th of 25
by date
Lead sponsor
4 of 25
Centre for Addiction and Mental Health

Among the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant, this one is the 20th largest by enrollment, is one of 6 that started in 2024, is one of 2 in phase 1, reaches primary completion later than 6 of the 13 other live ones, and was the 20th registered.

Depressive Disorder, Treatment-Resistant

450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 148 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

9 of the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About psilocybin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant, or all of them as a file.
02

Study summary

We propose a first-of-its-kind open-label clinical trial to investigate the feasibility, tolerability, and safety of administering psilocybin in autistic adults with treatment-resistant depression (TRD). In this study, 20 participants (intellectually able and fluent-speech adults) with autism and co-occurring TRD will receive manualized psychotherapy that has previously been used with psilocybin (Agin-Liebes et al., 2020). They will also receive psilocybin at 2 different time points, firstly a safety dose of 10mg, followed by a treatment dose of 25mg, separated by a week. This study design is in accordance with previous studies investigating the use of psilocybin with psilocybin-assisted therapy (PAT) to treat TRD (Carhart-Harris et al., 2016, 2018)

Read the detailed description

Each participant will begin with a screening visit (V1), during which eligibility will be determined through clinical and psychiatric assessments of the participant's physical and mental health. Following confirmation of eligibility, the study procedures will begin.

The participant will begin with a 2-4 week tapering period during which they will taper and discontinue any conventional antidepressants. Most conventional antidepressants will require a minimum 2-week tapering period, with the exception of fluoxetine, which will require a 4-week tapering period. Additional time may be added at the discretion of the study investigator. During the tapering period, there will be weekly check-ins with a study psychiatrist by in-person assessment or brief telephone calls to monitor for worsening depression and suicidality. Following the tapering period, participant eligibility will be re-assessed for the eligibility.

At Study Visit 2 (Baseline, V2), participants will be reassessed for eligibility following washout-period. Participants will complete a series of questionnaires and assessments (Table 2) and receive a brain MRI scan lasting for about 45 minutes as part of the baseline Visit 2. Further, participant will receive preparatory therapy (\~4 hours split across two different days) with trained study therapists which will be audio and video recorded. One of the preparatory therapy sessions will be conducted in-person. All therapy and dosing sessions will be audio and video recorded for participant safety, therapist oversight, and treatment fidelity monitoring as per the Audio and Video recording SOP.

At Study Visits 3 \& 4 (V3/V4), participants will receive oral doses of psilocybin (safety dose of 10 mg at V3, treatment dose of 25 mg at V4), to assess the tolerability and efficacy of psilocybin. These sessions will be held one week apart and will last 6 to 8 hours each. These sessions will take place in a pre-decorated treatment room at CAMH and will be audio and video recorded. Throughout the entire duration of the dosing sessions, participants will be monitored by a minimum of two trained therapists as per the audio \& video recording SOP. At the end of each session, participants will be evaluated for safety by a study psychiatrist before being discharged. Participants will also rate the 11-Dimension Altered States of Consciousness (11D-ASC) at the end of each dosing day when the subjective effects of psilocybin have subsided to a negligible level. In addition, the participant will also receive a second brain MRI scan lasting for about 30 minutes (V3a) following V3 Safety dosing. To reduce participant burden, MRI scan can be completed on the following day or within 1-3 days following safety dosing (V3). The participants will also be required to complete the self-rated questionnaires at this additional MRI assessment.

Visit 5 (V5) will be held one day after administration of the treatment dose (V4). During V5 the participants will complete post-treatment clinical and cognitive assessments, alongside the third and final MRI scan (of the main clinical trial design). Participants will also undergo a 1-hour integration therapy session to debrief their experiences the day before which will be in-person and will be audio and video recorded. Visit 6 (V6) will be held one week following the treatment dose (V4). During V6 a second 1-hour integration therapy session takes place virtually which will also be audio and video recorded. Further, all post-treatment clinical assessments will be repeated. Participants will also be required to complete the self-rated questionnaires. Subsequent clinical progress will be evaluated virtually at V7, V8, V9, which will respectively be held 2, 4, and 12 weeks following the treatment session (V4).

10 participants out of 20 participants in the main clinical trial could opt to receive 7 additional brain MRI scans besides the MRI scans at V2, V3a and V5 required in the main clinical trial. These 7 additional scans will be assessed at V1, in the middle of medication washout/tapering period V6, V7, V8, 8 weeks following the treatment dose (V4), and V9, respectively. Participants not taking prohibited medications (i.e., those who do not require a washout period) may skip the first two dense-sampling MRI scans and proceed to the main study MRI timepoint (V2) which is conducted as part of the baseline visit of the main study. In addition, participants may enroll at any point for the optional sub-study after obtaining optional consent form while main study visits remain active. At each optional MRI visit, self-rated assessments will also be collected.

03

Conditions studied

  • Treatment Resistant Depression
  • Autism Spectrum Disorder

Keywords

  • Treatment Resistant Depression
  • Autism Spectrum Disorder
  • psilocybin-assisted therapy
04

Who can participate

The criteria were revised on the registry on Oct 26, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be aged 18 to 65 years old;
  2. Must be deemed to have capacity to provide ;
  3. Ability to read and communicate in English;
  4. Must sign and date the informed consent form;
  5. Stated willingness to comply with all study procedures;
  6. Intellectually able: Either 1) the participant has a previous report showing intelligence quotient (IQ) ≥ 70 on the General Abilities Index of the Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) or any other standardized intelligence scales, or 2) the participant scores >10 percentile on the nine-item form of the Raven's Standard Progressive Matrices Test (RSPM).
  7. Clinical diagnosis of autism spectrum disorder (ASD), based on the or ICD-11
  8. Primary DSM-5 diagnosis of non-psychotic MDD, single or recurrent, based on the Mini International Neuropsychiatric Interview (MINI) administered at the first screening visit (V1);
  9. Participants diagnosed with treatment-resistant depression defined as individuals with a baseline GRID-HAMD-17 score > 14 and that have not responded to two or more separate trials of antidepressants at an adequate dosage and duration based on the Antidepressant Treatment History Form; there is no upper limit on the number of treatment failures;
  10. Ability to take oral medication;
  11. Individuals who are capable of becoming pregnant: use of highly effective for at least 3 months prior to screening and agreement to use such a method during study participation;
  12. Individuals who are willing to taper off current antidepressant and antipsychotic medications for a minimum of 2-weeks (or more depending on the medication) prior to Baseline (V2) and whose physician confirms that it is safe for them to do so; and
  13. A clean urine drug screen with the exception of cannabis (THC), where a positive result may be permitted at the discretion of the study PI in cases of known prior chronic use for medical purposes and documented abstinence (as specified under Section 4.5 Lifestyle considerations), given that THC metabolites may persist in urine for an extended period.
  14. A negative urine pregnancy test (in females).
  15. Agreement to adhere to Lifestyle Considerations (see below) throughout study duration

Exclusion criteria

Exclusion Criteria:

  1. Pregnant as assessed by a urine pregnancy test or individual's that intend to become pregnant during the study or are breastfeeding;
  2. Treatment with another drug or other intervention within 30 days of Screening (V1);
  3. The presence of an unstable seizure disorder as defined by having not been seizure-free for at least 6 months or anticonvulsant treatment has not been stable for at least 4 weeks;
  4. The presence of any or unstable medical conditions, including cardiovascular, liver, kidney, pulmonary disease, presence of known congenital brain malformation, as per investigator assessment based on medical history and chart review;
  5. Moderate or severe diagnosis of an alcohol or substance use disorder in the past 12 months;
  6. Any DSM-5 lifetime diagnosis of a schizophrenia-spectrum disorder, psychotic disorder (unless substance induced or due to a medical condition), bipolar I or II disorder, paranoid personality disorder, or neurocognitive disorder as determined by medical history and the MINI clinical interview;
  7. Any first-degree relative with a diagnosis of schizophrenia-spectrum disorder; psychotic disorder (unless substance-induced or due to a medical condition); or bipolar I or II disorder as determined by the family medical history form and discussions with the participant;
  8. Presence of a relative or absolute to psilocybin, including a drug allergy, recent stroke history, uncontrolled hypertension, low or labile blood pressure, recent myocardial infarction, cardiac arrhythmic, severe coronary artery disease, or moderate to severe renal or hepatic impairment;
  9. Substantial lifetime use (>10 years total) or recent use (past 6 months) of ketamine, psychedelics, or MDMA and positive urine toxicological screen at Screening (V1) and Baseline (V2);
  10. Any other clinically significant physical illness, including chronic infectious diseases or any other major concurrent illness that, in the opinion of the investigator, may interfere with the interpretation of the study results or constitute a health risk for the participant if they take part in the study;
  11. Have active suicidal ideation with intent and plan as determined by SBQ-ASC.
  12. Have initiated new psychotherapy within 12 weeks prior to Screening
  13. Contraindication to MR imaging or a previous history of claustrophobia.

Lifestyle considerations:

During this clinical trial, participants are asked to:

  • Abstain from alcohol for 24 hours before the intervention or the day of the intervention (V3, V4).
  • Abstain from the use of any prescribed opioids, benzodiazepines, or sleep aids (Z-drugs) within 12 hrs prior to the intervention (V3, V4) and for up to 6 hrs after administration.
  • Abstain from any illicit drugs (e.g. cocaine, ecstasy/MDMA, hallucinogens) for the duration of the study.
  • Abstain from any cannabinoids within 3 weeks prior to the intervention (V3, V4) and until the completion of the 2nd integrative therapy session (V6).
  • Abstain from driving or operating heavy machinery for up to 24 hours after the intervention (V3, V4).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Open-label

    Safety Dosing Session (V3): 10mg of psilocybin + therapy + safety evaluations Active Treatment Session (V4): 25mg of psilocybin + therapy + safety evaluations

    Drug: Psilocybin

Interventions

  • 2 dosing sessions 1 week apart, each about 6-8 hours duration Psilocybin-assisted therapy (PAT), is a psychotherapeutic intervention in which the psychological effects of psilocybin play a significant role. PAT procedures typically involve psychological preparation prior to therapist-supported psilocybin dosing sessions. These sessions are used to establish a therapeutic relationship, inform participants about what to expect, and set expectations for the dosing session. During the psilocybin dosing session, trained therapists support the individual through their experience and psychological integration therapy occurs after the dosing experience. PAT has shown impressive antidepressant effects in people with TRD or severe MDD in at least six modern-era clinical trials (Andersen et al., 2021).

    Also known as: Psilocybin-Assisted Therapy

06

What researchers measure

Primary outcomes

  1. Feasibility of Administering Psilocybin in Conjunction with Psychotherapy in Autistic Adults

    Percentage of participants recruited and retained.

    Time frame: From enrollment to end of treatment & follow-up at 12 weeks post-intervention (12 weeks post treatment dosing i.e., Day 0)

  2. Subjective Psychedelic Effects as Measured by the 11-Dimensions of Altered States of Consciousness (11D-ASC) Rating Scale

    A visual analogue scale (0-100 millimeters in length) with higher scores indicating more intense effects. Each question is attributable to one of the specified 11 dimensions of altered states of consciousness.

    Time frame: Administered following each dosing session (Visit 3 (Safety dosing - Day -7)) & Visit 4 (treatment dosing - Day 0))

  3. Number of Participants with Treatment-Related Adverse Events as Assessed by SBQ-ASC & UKU Side Effect Rating Scale

    Treatment-Related Adverse Events are expected to be similar in nature \& frequency to those reported in previous clinical studies on classic psychedelics in neurotypical populations. The UKU Side Effect Scale will be used to capture \& document core features of any treatment-related side effects. The Suicidal Behaviors Questionnaire - Autism Spectrum Conditions (SBQ-ASC) will be used to measure suicidality in participants. It consists of 5 scored items: 1) lifetime experience of suicidal thoughts; 2) frequency of intense suicidal thoughts in the last 12 months; 3) perseverative intense suicidal thoughts; 4) likelihood of suicide attempts; 5) communication of future suicide intent \& past suicide attempts to others. The SBQ-ASC also includes optional follow-up items which are not scored, based on responses to Item 5: for those who have attempted suicide, the follow-up items address presence of plans, impulsivity, and access to means.

    Time frame: From enrollment to end of treatment & follow-up at 12 weeks post-intervention (12 weeks post treatment dosing i.e., Day 0)

  4. Feasibility of Dense Sampling Brain MRI Procedures & Trial Design

    Percentage of participants recruited and retained for the optional dense sampling brain MRI procedures (multiple scans throughout duration of participant's involvement in study, up to 10 ).

    Time frame: From enrollment to end of treatment & follow-up at 12 weeks post-intervention (12 weeks post-treatment dosing i.e., Day 0)

Secondary outcomes

  1. Changes in Brain Network Interactions as Assessed with Pre- and Post-Intervention MRI Brain Scans

    Brain MRI scans and subsequent brain network \& cognitive modelling will be used to assess \& study changes in brain network interactions and possible mechanisms underpinning antidepressant effects of psilocybin for treatment-resistant depression in autism.

    Time frame: Evaluated using MRI before and after each dosing session (Visit 2 (Baseline Visit - Day -15 to -8)), Visit 3a (one day after safety dosing - Day -6)) & Visit 5 (one day after treatment dosing - Day 1))

  2. Changes & Variance in Brain Functional Connectivity Assessed Across Dense Sampling Brain MRI Sessions

    The optional dense sampling brain MRI procedures will allow for a more robust model of the brain and changes/variance that may be observed in an individual's brain over the course of the study, particularly in response to the intervention. Brain MRI scans and subsequent brain network \& cognitive modelling will be used to assess \& study changes in brain network interactions and possible mechanisms underpinning antidepressant effects of psilocybin for treatment-resistant depression in autism.

    Time frame: From enrollment to end of treatment & follow-up at 12 weeks post-intervention (12 weeks post treatment dosing i.e., Day 0)

Other outcomes

  1. Antidepressant Efficacy of Psilocybin-Assisted Psychotherapy for Autistic Adults with Treatment-Resistant Depression

    The following measures will assess antidepressant efficacy: Clinical Global Impression Scale (CGI) - Clinician-administered scale providing a brief, stand-alone assessment of the clinician's view of the participant's global functioning before and after initiating study medication. 7-point scale; higher scores indicate more severe symptoms. Beck Depression Inventory II (BDI-II) - 4-point scale measuring severity of depression and related symptoms; higher scores indicate more severe depressive symptoms. Snaith-Hamilton Pleasure Scale (SHAPS) - 4-point scale measuring hedonic capacity; lower scores indicate greater hedonic capacity (less anhedonia). Ruminative Responses Scale (RRS-10) - 4-point scale describing responses to depressed mood; higher scores reflect more severe rumination. Anxiety Scale for Autism - Adults (ASA-A) - 4-point scale measuring anxiety in autistic adults; higher scores indicate greater anxiety.

    Time frame: From enrollment to end of treatment & follow-up at 12 weeks post-intervention

  2. Changes in Psychological Symptoms & Features Theoretically Associated with Psilocybin-Assisted Psychotherapy & Depression

    General Alexithymia Factor Score (GAFS-8) - Self-report assessing difficulty identifying and describing feelings. Acceptance \& Action Questionnaire-II (AAQ-II) - Self-report measuring experiential avoidance and psychological inflexibility. Autism Burnout Survey Items (ABSI) - Self-report quantifying autistic burnout (exhaustion, withdrawal, cognitive overload) from stressors amplified in autistic individuals. Connor-Davidson Resilience Scale 10 (CD-RISC-10) - Measures resilience and flexibility in adapting to stressful situations. Interoception Sensory Questionnaire-8 (ISQ-8) - Measures perception and interpretation of interoceptive capacity. Interpersonal Needs Questionnaire (INQ-15) - Assesses 'thwarted belongingness' and 'perceived burdensomeness'. Cognitive Flexibility Inventory (CFI) - Self-report assessing cognitive flexibility in challenging and replacing maladaptive thoughts.

    Time frame: Administered at follow-up visits post-intervention (Visits 5-9)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — In the publication of the results of research, the investigators are obliged to preserve the confidentiality of all research participants. Participants will not be identified in any publication of research results. The results of this study will be published as group data without the use of characteristics that would identify individual participants. The study investigator will hold the primary responsibility for the publication of the results of the clinical trial. All publications will follow CAMH policies associated with publications.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jan 2027, 26 months after the start.

Of 19 phase 1 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 59. This study's planned 26 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Dec 2026 → Jan 2027 and completion Dec 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2024
First posted
Dec 12, 2024
StartActual
Nov 1, 2024
Primary completionEst.
Jan 2027was Dec 2026
CompletionEst.
Jan 2027was Dec 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2026→Jan 2027
Oct 26, 2026
Study completion
Dec 2026→Jan 2027
Oct 26, 2026
Enrollment
20 (estimated)→18 (actual)
Oct 26, 2026
Eligibility
1 inclusion criterion edited, 1 added
What changed in the criteria
Inclusion criteria
  • AddedA clean urine drug screen with the exception of cannabis (THC), where a positive result may be permitted at the discretion of the study PI in cases of known prior chronic use for medical purposes and documented abstinence (as specified under Section 4.5 Lifestyle considerations), given that THC metabolites may persist in urine for an extended period.
  • EditedA clean urine drug screen and negative urine pregnancy test (in females).
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Primary completion Dec 2026→Jan 2027
    Study completion Dec 2026→Jan 2027
    Enrollment 20 (estimated)→18 (actual)
    Eligibility 1 inclusion criterion edited, 1 added
    What changed in the criteria
    Inclusion criteria
    • AddedA clean urine drug screen with the exception of cannabis (THC), where a positive result may be permitted at the discretion of the study PI in cases of known prior chronic use for medical purposes and documented abstinence (as specified under Section 4.5 Lifestyle considerations), given that THC metabolites may persist in urine for an extended period.
    • EditedA clean urine drug screen and negative urine pregnancy test (in females).
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06731621
Responsible party
Sponsor
First posted
Dec 12, 2024
Start date
Nov 1, 2024
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Hsiang-Yuan Lin, MD
principal investigator · Centre for Addiction and Mental Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion